NCT05338892View on ClinicalTrials.gov

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

CompletedOBSERVATIONAL
Enrollment

595

Participants

Timeline

Start Date

June 22, 2022

Primary Completion Date

October 5, 2023

Study Completion Date

October 5, 2023

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
OTHER

Non-Interventional

No study treatment will be administered on this study.

Trial Locations (9)

14033

Regeneron Research Facility, Caen

45147

Regeneron Research Facility, Essen

60590

Regeneron Research Facility, Frankfurt

69310

Regeneron Research Facility, Pierre-Bénite

75010

Regeneron Research Facility, Paris

38 8036

Regeneron Research Facility, Graz

EC1A 7BE

Regeneron Research Facility, London

M20 4BX

Regeneron Research Facility, Manchester

NG5 1PB

Regeneron Research Facility, Nottingham

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY